LYRA (STOCKS)
Lyra Therapeutics, Inc. Common Stock
$1.370000
-0.100000 (-6.80%)
Prev close: $1.470000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Maria Palasis
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2.43M
- Employees
- 30
- P/E (TTM)
- -0.06
- P/B (TTM)
- -0.52
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-3.38 | $-5.36 | +1.9801 | +36.94% |
|
Jun 2025 (Q2)
|
$-5.51 | $-6.14 | +0.6304 | +10.27% |
|
Mar 2025 (Q1)
|
$-6.00 | $-6.97 | +0.9702 | +13.92% |
|
Dec 2024 (Q4)
|
$-8.00 | $-6.12 | -1.8800 | -30.72% |
Financial Statements
| Revenues | $600.00K |
| Benefits Costs and Expenses | $33.53M |
| Costs And Expenses | $33.53M |
| Nonoperating Income/Loss | $2.38M |
| Operating Expenses | $35.91M |
| Research and Development | $20.40M |
| Other Operating Expenses | $15.52M |
| Operating Income/Loss | -$35.31M |
| Income/Loss From Continuing Operations After Tax | -$32.95M |
| Income/Loss From Continuing Operations Before Tax | -$32.93M |
| Income Tax Expense/Benefit | $15.00K |
| Net Income/Loss | -$32.95M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$32.95M |
| Net Income/Loss Available To Common Stockholders, Basic | -$32.95M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $47.17 |
| Diluted Earnings Per Share | $47.17 |
| Basic Average Shares | 65,293,093 |
| Diluted Average Shares | 65,293,093 |
| Assets | $43.71M |
| Current Assets | $23.02M |
| Noncurrent Assets | $20.69M |
| Fixed Assets | $1.12M |
| Other Non-current Assets | $19.57M |
| Liabilities | $48.04M |
| Current Liabilities | $9.48M |
| Accounts Payable | $627.00K |
| Other Current Liabilities | $8.85M |
| Noncurrent Liabilities | $38.56M |
| Equity | -$4.33M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$4.33M |
| Liabilities And Equity | $43.71M |
| Net Cash Flow From Operating Activities | -$34.15M |
| Net Cash Flow From Operating Activities, Continuing | -$34.15M |
| Net Cash Flow From Investing Activities | $28.13M |
| Net Cash Flow From Investing Activities, Continuing | $28.13M |
| Net Cash Flow From Financing Activities | $4.27M |
| Net Cash Flow From Financing Activities, Continuing | $4.27M |
| Net Cash Flow | -$1.74M |
| Net Cash Flow, Continuing | -$1.74M |
| Comprehensive Income/Loss | -$32.97M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$32.97M |
| Other Comprehensive Income/Loss | -$6.00M |